KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.

Gonzalo Perez Marc, Lorena M Coria, Ana Ceballos, Juan Manuel Rodriguez, Mónica E Lombardo, Laura Bruno, Federico Páez Córdoba, Clara G Fascetto Cassero, Melina Salvatori, Mayra Rios Medrano, Fabiana Fulgenzi, María F Alzogaray, Analía Mykietiuk, Ignacio Leandro Uriarte, Nicolás Itcovici, Tomás Smith Casabella, Gonzalo Corral, Miriam Bruno, Oscar Roldán, Sebastián A Núñez, Florencia Cahn, Gustavo A Yerino, Alejandra Bianchi, Virginia Braem, Analía Christmann, Santiago Corradetti, Martín C Darraidou, Lucila Di Nunzio, Tatiana Estrada, Rocío López Castelo, Carla Marchionatti, Lucila Pitocco, Virgina Trias Uriarte, Cristian Wood, Romina Zadoff, Florencia Bues, Rosa M Garrido, Emanuele Montomoli, Alessandro Manenti, Laboratorio Pablo Cassará group for ARVAC, Agostina Demaría, Lineia Prado, Celeste Pueblas Castro, Lucas Saposnik, Jorge Geffner, Federico Montes de Oca, Julio C Vega, Juan Fló, Pablo Bonvehí, Jorge Cassará, Karina A Pasquevich, Juliana Cassataro

Vaccine 54 127045

PMID40179522
PMCID-
DOI10.1016/j.vaccine.2025.127045
发表日期2025-04-03
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

A randomized, placebo-controlled, crossover, double-blind, phase II/III study was conducted to evaluate the immunogenicity, safety, and tolerability of a recombinant booster vaccine (ARVAC) containing the SARS-CoV-2 spike protein receptor binding domain in three versions: ARVACGamma, ARVACOmicron, and ARVACBivalent in adults with ≤3 previous SARS-CoV-2 booster doses. Primary endpoint was seroconversion rate of neutralizing antibodies compared to placebo and to a > 75 % seroconversion rate to vaccine antigen homologous variants. All vaccine versions significantly increased seroconversion rates to SARS-CoV-2 variants compared to placebo. In participants aged 18-60 years, all versions met the primary endpoint; in those over 60 years old, ARVACOmicron and ARVACBivalent met this endpoint. No vaccine-related serious adverse events were recorded, and most adverse events were mild. Plasma levels of anti-spike-specific IgG and anti-S1-specific IgA in saliva increased in participants receiving any vaccine. The increase in plasma neutralizing antibodies induced by the vaccine was independent of the number of previous booster doses (0, 1 or 2), the primary vaccine platform (adenovirus, single-dose adenovirus, mRNA, inactivated virus, heterologous vaccination, and virus-like particle [VLP]) and the history of previous COVID-19. The neutralizing Ab response induced by the vaccine in healthy participants was similar to that triggered in participants with underlying medical conditions associated with an increased risk of severe COVID-19. ARVACBivalent induced high seroconversion rates (>90 %) against multiple variants and was superior to other ARVAC-versions. It increased neutralizing antibodies against SARS-CoV-2 variants (Ancestral, Gamma, Omicron, XBB and JN.1) and SARS-CoV-1. (NCT05752201).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。